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Reversible Proximal Renal Tubular Dysfunction after 
One-Time Ifosfamide Exposure
Introduction
The alkylating agent ifosfamide is an anti-neoplastic used in both
pediatric and adult age groups to treat various malignancies.
Although its potential for urologic toxicity is tempered by mesna
(sodium 2-mercaptoethane sulphonate) pretreatment, glomerulo-
pathy, tubulopathy, and hemorrhagic cystitis still occur as adverse
events in a considerable number of patients (1,2). Fanconi’s synd-
rome, a proximal tubulopathy marked by excessive urinary ex-
cretion of glucose, phosphate, bicarbonate, amino acid and protein,
is likewise a noted complication, with rickets and growth retardation
as long-term consequences. Adults are rarely affected, but this
syndrome is not infrequent in children as a clinical expression of
ifosfamide-induced nephrotoxicity (3,4). Several published reports
have also linked a combination of ifosfamide and cisplatin to
persistent renal function decline requiring hemodialysis (5). We
report here a 67-year-old patient who received a regimen of ifosfa-
mide, adriamycin and mesna for epithelioid sarcoma and soon there-
after developed a proximal renal tubulopathy, in conjunction with
hemorrhagic cystitis. To our knowledge, this is the first documented
instance where Fanconi’s syndrome (nephrotoxicity) and hemorrha-
gic cystitis (urotoxicity) jointly resulted from one-time ifosfamide
exposure, without contributory cisplatin.
Case Report
The patient, a 67-year-old male, presented at our clinic with dysu-
ria and gross hematuria. He had a 6-month history of type 2 diabetes
mellitus, treated with an oral hypoglycemic agent. More recently, a
malignancy was discovered when he sought treatment (debride-
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The alkylating agent ifosfamide is an anti-neoplastic used to treat various pediatric and adult
malignancies. Its potential urologic toxicities include glomerulopathy, tubulopathy and
hemorrhagic cystitis. This report describes a case of proximal renal tubular dysfunction and
hemorrhagic cystitis in a 67-year-old male given ifosfamide for epitheloid sarcoma. He was
also receiving an oral hypoglycemic agent for type 2 diabetes mellitus and had a baseline
glomerular filtration rate of 51.5 mL/min/1.73 m
2. Despite mesna prophylaxis, the patient ex-
perienced dysuria and gross hematuria after a single course of ifosfamide plus adriamycin.
The abrupt renal impairment and serum/urine electrolyte imbalances that ensued were
consistent with Fanconi’s syndrome. However, normal renal function and electrolyte status
were restored within 14 days, simply through supportive measures. A score of 8 by Naranjo
adverse drug reaction probability scale indicated these complications were most likely
treatment-related, although they developed without known predisposing factors. The
currently undefined role of diabetic nephropathy in adult ifosfamide nephrotoxicity merits
future investigation.
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ment) for an inflamed right fifth toe. Following amputation of the
right fourth and fifth toes and right inguinal lymphadenectomy, a
histologic diagnosis of epithelioid sarcoma was rendered. Following
pretreatment with mesna (4,350 mg/m
2), he subsequently received
one course of adriamycin plus ifosfamide (5 g/m
2 for one day).
Laboratory values at baseline included a serum creatinine of 1.3
mg/dL and a glomerular filtration rate of 51.5 mL/min/1.73 m
2. His
urine had tested negative for both protein and occult blood, with a
specific gravity of 1.1. 
Seven days after chemotherapy, the patient was admitted with a
blood pressure of 130/80 mmHg, a pulse rate of 80/min, a respiratory
rate of 20/min and a body temperature of 36.3℃. Percussion at the
costovertebral angle was pain-free, but palpation of the abdomen
elicited mild tenderness. The complete blood count showed white
blood cells (WBC) at 310/mm
3; lymphocytes, 220/mm
3; monocytes,
40/mm
3; neutrophils, 40/mm
3; eosinophils, 10/mm
3; hemoglobin,
13.1 g/dL; and hematocrit, 50,000/mm
3. A serum profile revealed a
creatinine of 1.9 mg/dL; sodium 129 mEq/L; potassium 2.4 mEq/L;
inorganic phosphorus 1.1 mg/dL; total magnesium 1.2 mg/dL; and
uric acid 0.7 mg/dL. Urinalysis displayed 1+ protein, 3+ glucose, and
red blood cells ＞100/HPF. As measured by 24-hour urine, total
protein was 1.5 g; inorganic phosphorus 2.55 g; and potassium 129
mEq/L. Arterial blood registered a pH of 7.28; HCO3 9.7 mmol/L;
and anion gap, 10.3 mmol/L (Table 1). The size and shadow of both
kidneys were normal by ultrasound, and a diffuse thickening of the
bladder wall was noted (Fig. 1).
By the second hospital day, the patient was febrile (39℃). Antibiotics
and granulocyte-colony stimulating factor (G-CSF) were initiated, and he
Fig. 1. Bladder ultrasonographic finding shows mild and diffuse
wall thickening of bladder wall.
Parameters Before chemotherapy After chemotherapy Normal values
Serum
BUN*(mg/dL) 15.6 32.9 8-23
Creatinine (mg/dL) 1.3 1.9 0.5-1.3
Sodium (mEq/L) 142 129 135-145
Potassium (mEq/L) 4.7 2.4 3.5-5
Total calcium (mg/dL) 9.6 8.4 8.4-10.2
Total magnesium (mg/dL) 2.5 1.2 1.9-2.5
Uric acid (mg/dL) 5.3 0.7 1-7
Inorganic phosphorus (mg/dL) 4.3 1.1 2.5-5.5
Glucose (mg/dL) 122 134 70-100
Urine
Protein (dipstick) Negative 1+ -
Glucose (dipstick) Negative 3+ -
RBC�(/HPF�) 0-1 > 100 0-4
Protein (g/L) ND
§ 1.5 0.02-0.12
Sodium (mEq/L) ND 240 40-220 
Inorganic phosphorus (g/24 hr) ND 2.55 0.4-1.3
Potasium (mEq/L) ND 129 25-125
Arterial blood gas analysis
pH  ND 7.28 7.35-7.45
pO2 (mmHg) ND 97.4 75-100 
pCO2 (mmHg) ND 18.5 35-48
HCO3
- (mmol/L) ND  9.7 21-28
O2Sat (%) ND 98.6 92-98.5
Anion gap (mmol/L) ND 10.3 10-20
Table 1. Laboratory findings before and after the first course of chemotherapy
*blood urea nigrogen, 
�red blood cell, 
�high power field, 
§ not done.Cancer Res Treat. 2010;42(4):244-246
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was given supportive fluid therapy. Bladder irrigation was also scheduled,
but was discontinued after one attempt due to severe pain and discomfort.
Most of the patient’s symptoms subsided by day 6 of hospitalization,
when he was afebrile with a normal neutrophil count, and the gross
hematuria had resolved. His urine samples were microscopically devoid
of organisms, and cultures of the urine and blood (each in triplicate) were
consistently negative. Without laboratory evidence of acute cystitis or
pyelonephritis (i.e., negative urinary nitrite and normalized WBC/CRP),
piperacillin/tazobactam antibiotic coverage was stopped. He was dis-
charged from the hospital after 14 days, having fully recovered.
The patient is seen periodically in follow-up at our outpatient
clinic. Urinalysis and a 24-hour urine test were unremarkable seven
days postdischarge, but his serum creatinine had climbed to 1.5
mg/dL. A score of 8 by Naranjo adverse drug reaction probability
scale indicated a strong likelihood that the proximal renal tubular
dysfunction experienced in this setting was linked to ifosfamide
therapy. Further adjuvant chemotherapy with the ifosfamide/adria-
mycin regimen was thus declined. 
Discussion
Risk factors for the nephrotoxicity of ifosfamide include cumu-
lative dosing, unilateral nephrectomy, and concomitant use of
cisplatin (1-3). Some studies, conducted with children or relative
youths, have also proposed that the associated risk may be age-de-
pendent (1). The applicability to adults is therefore questioned. Our
patient, while diabetic, was treatment naïve with respect to cancer
therapy and was not otherwise at risk as currently defined. He
nonetheless developed a proximal tubulopathy and hemorrhagic
cystitis (gross hematuria and lower abdominal pain) seven days
following a single course of ifosfamide-containing chemotherapy,
but finally recovered after two weeks of conservative treatment.
This certainly upholds the concept that ifosfamide may prove
nephrotoxic in the absence of reported risk factors.
The spectrum of ifosfamide nephrotoxicity is broad, ranging from
asymptomatic tubulopathy to overtly impaired renal function or
outright renal failure, and has been well documented (4). Even after
discontinuation of this drug, the tubulopathy may progress to end-
stage disease, so that hemodialysis is sometimes required. Our pa-
tient displayed features typical of Fanconi’s syndrome; hypopho-
sphatemia, hypokalemia, hypouricemia, proteinuria and glucosuria.
Although beta-2 microglobin and amino acids were not monitored,
the 24-hour urine results confirmed a proteinuria of 1.5 g/day and
high phosphorus output, together suggesting proximal tubular
damage.
The mechanism of ifosfamide nephrotoxicity has been attributed
to the metabolites 4-hydroxyl ifosfamide, chloracetaldehyde and
acrolein. Chloracetaldehyde, especially, suppresses activation of
complex-I (NADH-ubiquinone oxidoreductase) in the mitochondrial
respiratory chain, resulting in decreased intracellular glutathione and
ATP and inhibiting Ca
2+ signaling, thus inducing cell death. The
cellular impact of chloracetaldehyde, and hence the threat of
nephrotoxicity, cannot be averted with preventative use of mesna (5).
Hemorrhagic cystitis is a fairly regular accompanimont of ifos-
famide, manifested by dysuria, suprapubic discomfort, and gross or
microscopic hematuria. Although this complication is often
circumvented with mesna, it still occurs in a considerable number of
patients (6). The ifosfamide metabolite, acrolein, is subject to renal
excretion. It augments the production of nitric oxide synthase in
urothelium and generates various cytokines (TNF-αand IL-1β )
through intracellular transcription modulation to increase reactive
oxygen species and nitric oxide levels. Hemorrhagic cystitis thereby
results, variably involving mucosal edema, hemorrhage, necrosis
and ulceration.
The sulfhydryl radical of mesna combats ifosfamide urotoxicity
by combining with and eliminating acrolein (1). Proper hydration, of
course, is required; but the fact that mesna prophylaxis does not
uniformly prevent hemorrhagic cystitis in ifosfamide recipients
implies that direct urothelial insult by acrolein may not be the sole
pathogenic determinant. Perhaps cytokines such as TNF-α and IL-1
βand their roles in nitric oxide production provide an over-riding
mechanism for the urotoxicity of this drug (7).
This patient fortunately recovered with just two weeks of conser-
vative treatment. However, at follow-up, his serum creatinine level
had edged up to 1.5 mg/dL, and the nephropathy of diabetes was
implicated. Because his renal status may continue to deteriorate, he
is monitored periodically, with strict attention to blood glucose con-
trol. It is consequently our view that diabetic nephropathy, in addi-
tion to age as a risk factor, may trigger adult susceptibility to ifosfa-
mide nephrotoxicity. Further studies will be needed to confirm such
speculation.
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